VETTER-JECT
LIVE

Add to watchlist:

No watchlists yet
View on USPTO

VETTER-JECT Trademark

Serial Number: 79250207 • Registration: 6791709

VETTER-JECT is a trademark filed by VETTER PHARMA-FERTIGUNG GMBH & CO. KG on September 24, 2018. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 39 (Transportation & Storage), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

VETTER PHARMA-FERTIGUNG GMBH & CO. KG (15 trademarks)

2 SCHÜTZENSTR. 87 88212
RAVENSBURG , DE

Entity Type: 03

Trademark Details

Filing Date

September 24, 2018

Registration Date

July 19, 2022

Published for Opposition

May 3, 2022

Goods & Services

Bottling services, namely, bottling of liquid and solid substances, in particular of pharmaceuticals, medicines and solutions

Pharmaceutical preparations and medicines for the treatment of infections, cancer, depression, heart disease, vascular disease, intestinal disorder, lung and bronchial disfunction, liver disfunction, inflammation and inflammatory diseases, oral and laryngeal disease, optical and cranial disorders, arthritis, migraine, mucopolysaccharidosis, haemophilia, multiple sclerosis, osteoporosis, neuronal disorders, diabetes, erectile disfunction, infertility, crohn's disease, hereditary angioedema, thrombosis, encephalitis, diseases of the thyroid or parathyroid glands, metabolic diseases, muscular atrophy, disturbance of growth and anemia; pharmaceutical solutions for oral administration in the nature of sterile aseptic solutions, namely in the form of tablets, pills, capsules, drops, medical juice and medical syrup, all for the treatment of infections, cancer, depression, heart disease, vascular disease, intestinal disorder, lung and bronchial disfunction, liver disfunction, inflammation and inflammatory diseases, oral and laryngeal disease, optical and cranial disorders, arthritis, migraine, mucopolysaccharidosis, haemophilia, multiple sclerosis, osteoporosis, neuronal disorders, diabetes, erectile disfunction, infertility, crohn's disease, hereditary angioedema, thrombosis, encephalitis, diseases of the thyroid or parathyroid glands, metabolic diseases, muscular atrophy, disturbance of growth and anemia; injectable pharmaceuticals in the nature of antibody solutions, biologicals, peptides, polypeptides, proteins, enzymes, nucleic acids, coagulation factors, interferons, phosphonates and bisphosphonates, growth factors, hormones, hormoneantagonists, insulin, heparins, low molecular heparins and sulfur hexafluoride, all for the treatment of infections, cancer, depression, heart disease, vascular disease, intestinal disorder, lung and bronchial disfunction, liver disfunction, inflammation and inflammatory diseases, oral and laryngeal disease, optical and cranial disorders, arthritis, migraine, mucopolysaccharidosis, haemophilia, multiple sclerosis, osteoporosis, neuronal disorders, diabetes, erectile disfunction, infertility, crohn's disease, hereditary angioedema, thrombosis, encephalitis, diseases of the thyroid or parathyroid glands, metabolic diseases, muscular atrophy, disturbance of growth and anemia; eyedrops, contact lens solutions; medicated compresses; medical plasters, materials for dressings in the nature of bandages, wadding and gauze; filled medical injection devices, in particular syringes and instruments for injections, injectors, auto-injectors and single-chamber and dual-chamber disposable syringes, all sold filled with pharmaceutical preparations for the treatment of infections, cancer, depression, heart disease, vascular disease, intestinal disorder, lung and bronchial disfunction, liver disfunction inflammation and inflammatory diseases, oral and laryngeal disease, optical and cranial disorders, arthritis, migraine, mucopolysaccharidosis, haemophilia, multiple sclerosis, osteoporosis, neuronal disorders, diabetes, erectile disfunction, infertility, crohn's disease, hereditary angioedema, thrombosis, encephalitis, diseases of the thyroid or parathyroid glands, metabolic diseases, muscular atrophy, disturbance of growth and anemia

Empty medical injection devices, in particular syringes and instruments for injections, injectors, auto-injectors and single-chamber and dual-chamber disposable syringes, all sold empty; medicine containers for administering medicines, of glass and/or plastic in the nature of medical syringes, injectors, auto-injectors, disposable syringes and disposable cannulae; syringe holders being containers specially adapted for holding medical syringes; medical syringes, disposable syringes, and disposable cannulae sold either individually or in combination, all for medical purposes

Development of syringes and instruments for injections, injectors and packaging for the aforesaid goods; laboratory tests in the nature of scientific testing in the fields of chemical, physics and process engineering; product development and conducting of scientific tests in the fields of pharmacological and microbiological processes

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Nov 14, 2022 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Oct 22, 2022 FICS
FINAL DISPOSITION PROCESSED
Oct 22, 2022 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Oct 19, 2022 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jul 19, 2022 NRCC
REGISTERED-PRINCIPAL REGISTER
Jul 19, 2022 R.PR
NOTIFICATION PROCESSED BY IB
May 9, 2022 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 3, 2022 NPUB
PUBLISHED FOR OPPOSITION
May 3, 2022 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Apr 13, 2022 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Apr 13, 2022 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 13, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 27, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 26, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 25, 2022 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Mar 25, 2022 ERFR
NOTIFICATION OF SUBSEQUENT FINAL EMAILED
Sep 27, 2021 GNS1
CONTINUATION OF FINAL REFUSAL E-MAILED
Sep 27, 2021 GNCF
ACTION CONTINUING A FINAL - COMPLETED
Sep 27, 2021 CNCF
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Jul 28, 2021 RCCK
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
May 16, 2021 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Apr 28, 2021 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Apr 28, 2021 OPNR
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Oct 2, 2020 RCSC
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Mar 12, 2020 GNS3
LETTER OF SUSPENSION E-MAILED
Mar 12, 2020 GNSL
SUSPENSION LETTER WRITTEN
Mar 12, 2020 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 10, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 10, 2020 CRFA
ASSIGNED TO LIE
Mar 10, 2020 ALIE
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Mar 5, 2020 GNS3
LETTER OF SUSPENSION E-MAILED
Mar 5, 2020 GNSL
SUSPENSION LETTER WRITTEN
Mar 5, 2020 CNSL
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Mar 4, 2020 ERFR
CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Dec 6, 2019 CORN
CORRECTION TRANSACTION RECEIVED FROM IB
Nov 29, 2019 CRCV
NOTIFICATION OF FINAL REFUSAL EMAILED
Sep 5, 2019 GNFN
FINAL REFUSAL E-MAILED
Sep 5, 2019 GNFR
FINAL REFUSAL WRITTEN
Sep 5, 2019 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 13, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 13, 2019 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 13, 2019 TROA
REFUSAL PROCESSED BY IB
Mar 2, 2019 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Feb 13, 2019 RFCS
REFUSAL PROCESSED BY MPU
Feb 12, 2019 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Feb 5, 2019 RFCR
NON-FINAL ACTION WRITTEN
Feb 4, 2019 CNRT
APPLICATION FILING RECEIPT MAILED
Feb 1, 2019 MAFR
ASSIGNED TO EXAMINER
Jan 28, 2019 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 28, 2019 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jan 24, 2019 REPR